ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

NCI National Lab’s Budget to Grow Over Its $299.2 Million FY2013 Level

February 28, 2014

Cancer Clinical Trials System Needs Comprehensive Review, NCI Director Says

July 11, 2003

In Brief: NCI Names Rice To Head Frederick Center; NIAID Appoints Killen DAIDS Director

April 22, 1994

FCRC Committee Limited To Review Of Basic Science

November 26, 1976

In Brief: Beahrs, Murphy, Quan Honored By SSO; AACR Award Mulligan, Wiggler, Sporn, Witte

March 29, 1991

Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage

May 31, 2013